Funding the Practice: What Lenders Fund and Why

A rheumatology practice is a capital-light medical specialty compared with surgical or imaging-heavy fields, which makes it a comfortable fit for debt financing rather than equity. The dominant route in the United States is the SBA 7(a) loan, which funds practice start-ups, partner buy-ins, and full practice acquisitions up to $5 million. Medical and dental practices are one of the most heavily approved categories in the 7(a) book because the borrower is a licensed professional with durable, insurance-backed cash flow. Lenders read that as low default risk.

For an independent rheumatology start-up, a realistic 7(a) request sits between $150,000 and $450,000, with the bank typically asking for a 10% borrower equity injection and a personal guarantee. Loan terms run up to 10 years for working capital and equipment and up to 25 years when real estate is involved. A practice acquisition 7(a) loan is often larger, because you are buying an existing patient panel and payer contracts rather than building them from zero. Equipment financing and infusion-chair leasing sit alongside the 7(a) for founders who want to keep the loan principal lower.

In the United Kingdom the funding picture is different. Private rheumatology consultants more often self-finance the first chambers room and a sessional clinic, then scale once referral volume is proven. Where external capital is needed, the government-backed Start Up Loan provides up to £25,000 per founder at a fixed 6% with free mentoring, and high-street banks offer professional practice loans secured against projected fees. A two-partner UK practice frequently combines two Start Up Loans with a commercial overdraft facility for drug-purchase working capital. Whichever route you take, the lender or investor reads the same three pages first: the demand evidence, the use-of-funds table, and the month-by-month cash position. The Avvale template puts those three in front.

What separates a funded rheumatology plan from a rejected one is rarely the headline revenue number. It is whether the cash-flow page survives scrutiny. Two questions sink most applications. First, can you cover the buy-and-bill drug float, the gap between paying for a biologic and being reimbursed for it, without running dry? Second, have you built in the credentialing lag, the 60-to-120-day window where the doors are open but insured claims are not yet payable? A lender who sees both addressed up front treats the rest of the plan as credible. A lender who has to ask treats the whole document as optimistic. The Avvale template forces both onto the page.

Equity investment is the less common route, but it appears in two situations: a multi-physician group raising growth capital to add infusion capacity or a second location, and a platform or MSO acquiring practices to build a regional network. In both cases the buyer is underwriting enterprise value, which in rheumatology is driven far more by the infusion and ancillary lines than by professional fees. If raising equity is on your roadmap, the plan should separate the salary-substitute economics of the founding physician from the transferable, scalable economics a buyer would actually pay a multiple on.

If you want to compare adjacent specialty economics before you commit, our medical clinic business plan template covers the broader outpatient model, and the bespoke business plan service builds the full lender package for you.

Demand, Shortage & Market Size

Rheumatology is one of the few specialties where the investment thesis writes itself, because demand structurally outstrips supply. The United States has just 5,667 clinically active rheumatologists, and workforce modelling projects a 2025 deficit of 2,576 adult rheumatologists relative to patient need. The maldistribution is severe: 72 of every 100 US counties have zero clinically active rheumatologists, and 93 of 100 rural jurisdictions have none. Half the existing workforce is over 55, so a retirement cliff is approaching.

Source: ACR Convergence Today / The Rheumatologist, 2025

For a founder, this is the most important slide in the deck. It means a new practice in an underserved metro or a rural-adjacent town does not have to win patients from a competitor; it has to absorb unmet demand that is already there. Long wait times at incumbent groups become your referral pipeline.

On the spending side, the global rheumatology therapeutics market was valued at $28.75 billion in 2024 and is forecast to reach $38.34 billion by 2033 at a 3.4% CAGR. North America alone holds 41.32% of global revenue. Disease-modifying anti-rheumatic drugs (DMARDs) make up 55.45% of the market, and rheumatoid arthritis is the single largest indication at 41.17%.

Source: Astute Analytica via GlobeNewswire, 2025

The takeaway for your plan: a rheumatology practice sells two things at once. It sells access to a scarce specialist, and it sells administration of a large and growing class of biologic and DMARD therapies. The first is why patients show up; the second is where a meaningful share of the margin sits. A plan that only counts consult fees understates the business.

The therapeutics market is also in the middle of a structural shift that affects your margin assumptions. Astute Analytica describes the field pivoting from legacy injectables toward precision oral therapies and cost-efficient biosimilars, driven by an expanding patient population, with roughly 18 million new rheumatoid-arthritis cases globally in 2024. For an independent practice, the rise of biosimilars is a double-edged number: lower drug acquisition cost can compress the per-unit buy-and-bill spread, but it also expands the pool of patients who can be put on therapy at all. A credible plan models both effects rather than assuming today's reimbursement spreads hold for five years.

In the United Kingdom the demand picture is structurally similar even though the payment model differs. NHS rheumatology waiting lists have lengthened, and that backlog is precisely what feeds the private and self-pay market: patients and employers willing to pay for faster access to a consultant. A UK plan should size the local private catchment, name the nearest NHS trusts whose waits create overflow, and be explicit about whether revenue comes from private medical insurance, self-pay, or NHS-contracted sessional work, because each has a different collection profile.

What It Costs to Open the Doors

A new independent rheumatology practice typically needs $95,000 to $480,000 in the United States, or roughly £70,000 to £360,000 in the United Kingdom. The range is wide because the model decision dominates everything else: a consult-only clinic sharing an existing building lands near the bottom, while a standalone practice with a multi-chair infusion suite and point-of-care imaging lands near the top. Below is the line-item structure the template fills in.

Cost Breakdown

• Clinic fit-out, exam rooms, point-of-care ultrasound: $40K–$160K (£30K–£120K). Musculoskeletal ultrasound is increasingly expected for joint injections and is a credible differentiator.
• Infusion suite build-out + chairs: $45K–$120K (£35K–£95K). Basic equipment and supplies start near $10K–$15K, but space modifications, staffing, and state-specific build-out push the realistic figure well above $45K.
• Rheumatology EHR + practice-management software: $8K–$28K per year. Specialty platforms such as ModMed EMA, Nextech, and PrognoCIS handle infusion scheduling, biologic dosing, and prior-authorisation workflows.
• Credentialing, payer enrollment + malpractice: $15K–$60K (£12K–£48K). Includes Medicare PECOS enrollment and a $1M/$3M malpractice minimum in most states.
• Drug-inventory float for buy-and-bill biologics: a revolving line, not a one-time cost. You purchase the drug before the payer reimburses, so the cash gap must be funded.
• Working capital / reserves: $30K–$90K (£24K–£70K). Hold three to six months of operating cash because credentialing delays the first insured collections.

Infusion and cost ranges informed by Barton Associates Rheumatology Salary Guide, 2025 and Avvale planning models.

Funding Routes

In the US, the SBA 7(a) loan (up to $5M) is the workhorse, supported by equipment financing and infusion-chair leasing. In the UK, the government-backed Start Up Loan (up to £25,000 at 6% fixed) plus a professional practice loan or commercial overdraft for drug working capital is the common stack. Many founders blend personal savings with a bank facility so the equity injection is met without over-borrowing.

A practical financing structure for an infusion-integrated US start-up often layers three instruments. A 7(a) term loan funds the build-out, equipment, and credentialing. A separate revolving line of credit, sized to peak monthly drug spend, funds the buy-and-bill float so biologic purchases never compete with payroll for cash. And equipment leasing keeps the infusion chairs and point-of-care ultrasound off the term loan, preserving borrowing capacity. Presenting the capital stack this way, rather than as one undifferentiated number, tells a lender you understand that a rheumatology practice has two distinct cash needs: a one-time launch cost and an ongoing drug-inventory cycle.

How a Rheumatology Practice Makes Money

Rheumatology revenue is built on relative value units. At a median of roughly 5,200 work RVUs per physician and about $58 per wRVU, a single rheumatologist produces near $302,000 in professional collections before any ancillary revenue. Most rheumatologists earn $325,000 to $350,000 in total compensation, with infusion ownership pushing the high end materially higher.

Source: Barton Associates, 2025

The revenue stack for an independent practice usually breaks into four streams:

• Professional fees: new-patient consults ($200–$450), follow-ups ($120–$250), and joint injections.
• Buy-and-bill infusions: the practice purchases biologics and DMARDs, administers them in-suite, and bills the payer the drug plus an administration fee. This is the largest single margin lever for most independent practices.
• Ancillary diagnostics: point-of-care musculoskeletal ultrasound, bone-density (DXA) scanning, and in-office lab work under a CLIA certificate.
• Research and trials: mature practices add pharmaceutical clinical-trial site revenue, which is high-margin and counter-cyclical.

Industry operating margins land between 12% and 28% once a practice matures. The variance is driven almost entirely by infusion volume and payer mix. A consult-only practice with a heavy Medicare panel will sit at the low end; a practice with a busy infusion suite and a balanced commercial-insurance mix will sit at the high end.

Payer mix deserves its own line in the plan because it changes both revenue and risk. Medicare reimburses predictably but at lower rates, and its drug-reimbursement methodology compresses the buy-and-bill spread. Commercial insurers pay more but demand more prior-authorisation work. Medicaid pays least and slowest. A practice that models a realistic blend, rather than assuming a best-case commercial-heavy panel, produces a forecast that survives a lender's stress test. The plan should also show how the mix is expected to shift as the panel matures, because early referrals often skew toward whichever payer the founding referrers serve.

Chair utilisation is the operational metric that ties the revenue model together. An infusion suite is a fixed-cost asset: the rent, the nurse, and the build-out are paid whether a chair is full or empty. Every additional infusion that fills an otherwise idle chair drops almost entirely to contribution. That is why the financial model should track scheduled-chair-hours against capacity, and why a practice that runs its suite at 70% utilisation can be dramatically more profitable than one running at 40% on the same cost base.

Three Practice Models Compared

The single biggest decision in the plan is which model you build. Each has a different capital requirement, a different break-even, and a different story for a lender. The template lets you model all three and pick the one your local market supports.

The management-services-organisation (MSO) route deserves attention. Networks like Bendcare and United Rheumatology aggregate group-purchasing power on expensive biologics, which directly improves infusion margin, and they shoulder some of the credentialing and prior-authorisation burden. Large independent groups such as Articularis Healthcare and Arthritis & Rheumatism Associates show what the scaled version of each model looks like in practice. Your plan should state plainly which model you are building and why your local payer mix and referral base support it.

Credentialing, Licensing & Compliance

Licensing for a rheumatology practice is more demanding than for a generic clinic because you administer high-cost biologics and, frequently, controlled substances. Sequence the steps below before you sign a lease, because credentialing is the long pole that determines when you can bill.

United States

• NPI + Medicare/Medicaid (PECOS) enrollment — CMS; NPI is free, institutional PECOS carries a ~$709 fee; 60–120 days.
• Commercial payer credentialing — per-payer; you cannot bill insured visits until each is complete.
• CLIA certificate for in-office labs — CMS; $180–$1,200/yr by category; 6–8 weeks.
• DEA registration + state controlled-substance registration — DEA; $888 per 3 years; 4–6 weeks.
• State medical-facility or office-based-infusion license — state health department; cost and timeline vary.
• Malpractice insurance — $1M/$3M minimum in most states; and HIPAA compliance program.

United Kingdom

• GMC Specialist Register (rheumatology) — General Medical Council; £433 annual retention; the CESR route can take 3–6 months.
• Care Quality Commission (CQC) registration — required to provide regulated activities; around £1,743/yr per site (new-provider application near £1,522); 10–16 weeks.
• Medical indemnity cover — MDU, MPS, or a private insurer; £3K–£30K+/yr depending on activity.
• Clinical waste disposal licence and information-governance / UK GDPR compliance.

UK figures: GMC Specialist Register and CQC registration costs, 2026.

Australia & Canada

• Australia: AHPRA medical registration; state day-procedure / private-hospital facility licensing; Medicare provider number for billing.
• Canada: provincial college registration (for example CPSO in Ontario); a provincial billing number (OHIP, MSP); and a CRA business number.

Target Market & Referral Strategy

A rheumatology practice does not acquire patients the way a retail clinic does. The buyer who matters most is not the patient; it is the referrer. Primary-care physicians, orthopaedic surgeons, nephrologists, and dermatologists send the patients who fill your schedule, and they send them to the rheumatologist who answers the phone, returns notes quickly, and has a short wait. Your business plan should treat referral relationships as the core distribution channel and model them explicitly.

On the patient side, the demographic skews toward adults aged 40 and over with chronic inflammatory conditions: rheumatoid arthritis, psoriatic arthritis, lupus, gout, ankylosing spondylitis, and osteoporosis. These are lifelong conditions, which means a rheumatology patient is rarely a one-time visit. The lifetime value of a single retained patient on a biologic regimen, returning for infusions and monitoring, dwarfs the value of a one-off consult. That retention dynamic is the quiet reason the economics work, and it belongs in the plan.

• Primary referrers: local primary-care groups whose patients face long waits at incumbent rheumatology practices. Quantify those wait times; they are your opening.
• Specialist referrers: orthopaedics, nephrology, and dermatology, where overlapping inflammatory and autoimmune presentations are common.
• Retained patients: chronic-disease patients on long-term DMARD or biologic therapy who anchor recurring infusion and monitoring revenue.
• Self-referral / private-pay: in the UK private market and US cash-pay niches, patients seeking faster access than the NHS or an overloaded local system can provide.

The strongest plans show a concrete number for each segment: how many active referrers exist within the catchment, the average new-patient referrals each can send per month, and the conversion to a retained panel. That turns a vague demand narrative into a forecast a lender can stress-test. It also reframes the workforce shortage from a macro statistic into a local one: if the nearest competing practice has a ten-week new-patient wait, every week you shave off that figure is a referrer you can win.

Operations, Staffing & Workflow

Operations is where rheumatology margin is won or lost, because two of the practice's biggest cost and revenue drivers, prior authorisation and infusion scheduling, are operational problems before they are clinical ones. A biologic that is administered late because a prior authorisation stalled is a delayed payment and an unhappy patient. The plan should show the systems that prevent that.

The Staffing Curve

New practices ramp over 12 to 18 months, and the most common cash error is staffing for the year-three target on day one. A defensible Year-1 model for a solo-to-two physician practice usually runs:

• Physician(s): the founder, plus a second rheumatologist or an advanced-practice provider (nurse practitioner or PA) added once volume justifies it.
• Infusion nurse(s): sized to chair count and infusion-day schedule; the binding constraint on infusion revenue.
• Medical assistants: rooming, injections, vitals, and patient flow.
• Prior-authorisation / billing specialist: the most important administrative hire in rheumatology; biologic approvals live or die here.
• Front desk / practice coordinator: scheduling, referrals intake, and credentialing follow-up.

Systems and KPIs

Specialty EHR platforms such as ModMed EMA, Nextech, and PrognoCIS synchronise biologic dosing, refrigeration logs, chair allocation, and prior authorisations, which removes the manual scheduling friction that quietly caps infusion throughput. Whichever platform you choose, define owner-level KPIs from day one: chair-utilisation rate, days-in-A/R, prior-authorisation turnaround time, new-patient wait time, and net collections per wRVU. Reporting discipline early is what makes a weak spot visible before it becomes structural.

The operations section should also document the core clinical and infusion workflows so quality is repeatable as the practice scales, and it should state the supplier and group-purchasing arrangements that govern drug acquisition cost, since those terms move the infusion margin directly.

Marketing & Patient Acquisition

Because referrers drive the schedule, rheumatology marketing is mostly business-to-business relationship building, not consumer advertising. The acquisition plan should connect specific channels to the patient-volume forecast rather than chasing broad awareness.

• Referrer outreach: direct relationships with primary-care and specialist practices, fast turnaround on consult notes, and a published short wait time. This is the highest-return channel and the cheapest.
• Local search and listings: a clinical website, accurate directory and insurance-network listings, and condition-specific pages so patients searching for a local rheumatologist find you. Given that 72 of 100 US counties have none, local intent converts well.
• Patient retention loops: recall systems for monitoring labs and infusions turn a treated patient into recurring, predictable revenue and into referrals through word of mouth.
• Professional credibility: American College of Rheumatology membership, point-of-care ultrasound capability, and clinical-trial participation all signal quality to referrers and patients.

Tie each channel to a cost per acquired referrer, a conversion rate to retained patients, and a payback period, so the sales forecast rests on a real acquisition model rather than optimism. For most practices, the founder's own time spent building referrer relationships in the first six months is the highest-return marketing investment available.

Five Costly Mistakes to Avoid

Across the medical practices we have helped fund, the same avoidable errors recur. Each one is a question a sharp lender will ask, so address them in the plan before they do.

• Underbudgeting the buy-and-bill drug float. You pay for biologics weeks before the payer reimburses. Without a revolving line sized to peak infusion volume, a profitable practice can still run out of cash.
• Opening before credentialing completes. Seeing insured patients you cannot yet bill burns 2–4 months of revenue. Start PECOS and commercial credentialing during the build-out, not after.
• Overstaffing for volume that takes 12–18 months to build. New practices ramp gradually. Match clinical and admin headcount to the patient-panel growth curve, not to the year-three target.
• Skipping the referral-source feasibility study. Map local primary-care and orthopaedic referrers, and quantify incumbent wait times, before committing to a lease. The shortage helps you only if referrers know you exist.
• Treating the infusion suite as optional. For most independent rheumatology practices the infusion suite is the primary margin engine. A plan that defers it without a clear reason understates both revenue and enterprise value.

Rheumatology Practice Glossary

A handful of terms recur in every rheumatology plan and every lender conversation. Getting them right in the document signals that the founder understands the business, not just the medicine.

• Buy-and-bill: the practice purchases a biologic or infused drug, administers it in-suite, and bills the payer for the drug plus an administration fee. The largest margin lever in most independent practices.
• DMARD: disease-modifying anti-rheumatic drug. The treatment backbone for inflammatory arthritis and 55.45% of the therapeutics market by drug type.
• wRVU: work relative value unit, the standard unit of physician productivity. Rheumatology runs a median near 5,200 wRVU per physician at roughly $58 per unit.
• Prior authorisation: payer approval required before an expensive biologic can be administered. Turnaround time directly affects cash flow and patient satisfaction.
• Credentialing / PECOS: the enrollment process with Medicare and commercial payers. Until it completes you cannot bill insured visits.
• Infusion suite: the in-office treatment area with infusion chairs where biologics are administered. The primary enterprise-value driver for an independent practice.
• MSO / GPO: management-services or group-purchasing organisation (for example Bendcare, United Rheumatology) that pools drug-buying power and shoulders administrative load.

Sample Business Plan Preview

Preview the structure and financial outputs a buyer receives. These mockups are generated from the same assumptions used throughout this page.

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for a rheumatology practice:

• Executive Summary — your practice at a glance, written to win a lender in 60 seconds.
• Company Overview — legal structure, ownership, location, and the founder's clinical background.
• Market & Demand Analysis — local shortage data, referral mapping, and incumbent wait times.
• Service & Infusion Model — consult, injection, infusion, and diagnostic lines defined.
• Competitor Analysis — local groups, MSO options, and your differentiation.
• Marketing & Referral Plan — how primary-care and orthopaedic referrers find you.
• Operations Plan — credentialing timeline, staffing curve, and EHR workflow.
• Management Team — physician bios, advisory clinicians, and planned hires.

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, a buy-and-bill drug-float schedule, and a startup capital requirements table.

Frequently Asked Questions

Useful Links & Resources

Related Avvale resources for founders building a rheumatology or wider healthcare practice:

• Browse all free business plan templates
• Market research & content service
• Work with an Avvale business plan writer